Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants
Restricted accessResearch articleFirst published online May, 2018
Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants
Heparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated complication of unfractionated heparin (UFH) and low molecular weight heparin therapy. HIT is characterized by moderate thrombocytopenia 5-10 days after initial heparin exposure, detection of platelet-activating anti-platelet factor 4/heparin antibodies and an increased risk of venous and arterial thrombosis. Extracorporeal membrane oxygenation (ECMO) is a form of mechanical circulatory support used in critically ill patients with respiratory or cardiac failure. Systemic anticoagulation is used to alleviate the thrombotic complications that may occur when blood is exposed to artificial surfaces within the ECMO circuit. Therefore, when HIT complicates patients on ECMO support, it is associated with a high thrombotic morbidity and mortality. The following article reviews the current knowledge in pediatric HIT, especially in ECMO patients, and the alternative anticoagulation options in the presence of HIT.
Revel-VilkS. The conundrum of neonatal coagulopathy. Hematology20122012: 450–454.
3.
WarkentinTE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost1999; 82: 439–447.
4.
GreinacherAFarnerBKrollHKohlmannTWarkentinTEEichlerP. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost2005; 94: 132–135.
5.
WarkentinTEMaurerBTAsterRH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med2007; 356: 2653–2655. Discussion 2655.
6.
AmiralJBrideyFDreyfusMet al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost1992; 68: 95–96.
7.
GreinacherAPötzschBAmiralJDummelVEichnerAMueller-EckhardtC. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost1994; 71: 247–251.
8.
VisentinGPFordSEScottJPAsterRH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest1994; 93: 81–88.
9.
WarkentinTERobertsRSHirshJKeltonJG. Heparin-induced skin lesions and other unusual sequelae of heparin-induced thrombocytopenia syndrome. Chest2005; 127: 1857–1861.
10.
GreinacherAJuhlDStrobelUet al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost2007; 5: 1666–1673.
11.
PriceEAHaywardCPMoffatKAMooreJCWarkentinTEZehnderJL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost2007; 98: 1357–1361.
12.
WarkentinTE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program2011; 2011: 143–149.
13.
WarkentinTESheppardJAHorsewoodPSimpsonPJMooreJCKeltonJG. Impact of the patient population on the risk for heparin induced thrombocytopenia. Blood2000; 96: 1703–1708.
14.
PouplardCAmiralJBorgJYLaporte-SimitsidisSDelahousseBGruelY. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol1999; 111: 700–706.
15.
MartelNLeeJWellsPS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood2005; 106: 2710–2715.
16.
WarkentinTEKeltonJG. A 14-year study of heparin-induced thrombocytopenia. Am J Med1996; 101: 502–507.
17.
SpadoneDClarkFJamesELasterJHochJSilverD. Heparin-induced thrombocytopenia in the newborn. J Vasc Surg1992; 15: 306–311. Discussion 311–312.
18.
SeverinTSutorAH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost2001; 27: 293–299.
19.
AvilaMLShahVBrandaoLR. Systematic review on heparin-induced thrombocytopenia in children: a call to action. J Thromb Haemost2013; 11: 660–669.
20.
VakilNHKanaanAODonovanJL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther2012; 17: 12–30.
21.
TakemotoCMStreiffMB. Heparin-induced thrombocytopenia screening and management in pediatric patients. Hematology Am Soc Hematol Educ Program2011; 2011: 162–169.
22.
RischLFischerJEHerklotzRHuberAR. Heparin-induced thrombocytopenia in pediatrics: clinical characteristics, therapy, outcomes. Intensive Care Med2004; 30: 1615–1624.
23.
WarkentinTEGreinacherA. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg2003; 76: 638–648.
WarkentinTEGreinacherAKosterA. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?Ann Thorac Surg2009; 87: 1633–1640.
28.
GuYJvan OeverenWAkkermanCBoonstraPWHuyzenRJWildevuurCR. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg1993; 55: 917–922.
29.
FeyrerRHarigFCesnjevarR. Bioline or safeline treatment of CPB circuits?Cardiovasc Eng2003; 8: 79–84.
30.
Sakiyama-ElbertSE. Incorporation of heparin into biomaterials. Acta Biomater2014; 10:1581–1587.
31.
PappalardoFMajGScandroglioASampietroFZangrilloAKosterA. Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion2009; 24: 135–137.
32.
DolchMEFreyLHatzRet al. Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin induced thrombocytopenia. Exp Clin Transplant2010; 8: 329–332.
KosterAWengYBöttcherWGromannTKuppeHHetzerR. Successful use of bivalirudin as anticoagulant in ECMO in a patient with acute HIT. Ann Thorac Surg2007; 83: 1865–1867.
35.
SokolovicMPrattAKVukicevicVet al. Platelet count trends and prevalence of heparin-induced thrombocytopenia in a cohort of extracorporeal membrane oxygenator patients. Crit Care Med2016; 44: e1031–e1037.
36.
DeitcherSTopoulosAPBartholomewJRKichuk-ChrisantM. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr2002; 140: 264–266.
37.
MejakBGiacomuzziCHellerEet al. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol2004; 36: 178–181.
38.
TchengWYWongWY. Successful use of argatroban in pediatric patients requiring anticoagulant alternatives to heparin. Blood2004; 104:4085.
39.
AlsoufiBBoshkovLKKirbyAet al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Cardiac Surg Annu2004; 7: 155–157.
40.
DagerWEGosselinRCYoshikawaROwingsJT. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation. Ann Pharmacother2004; 38: 598–601.
41.
ScottLKGrierLRConradSA. Heparin-induced thrombocytopenia in a patient receiving extracorporeal membrane oxygenation with argatroban. Pediatr Crit Care Med2006; 7: 473–475.
42.
KnodererCAKnodererHMTurrentineMWKumarM. Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient. Pharmacotherapy2006; 26: 709–712.
43.
PotterKERajASullivanJE. Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support. J Pediatr Hematol Oncol2007; 29: 265–268.
44.
PollakUYacobobichJTamaryHDaganOManor-ShulmanO. Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature. J Extra Corpor Technol2011; 43: 5–12.
45.
NagleELDagerWEDubyJJet al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med2013; 14: e182–e188.
46.
PrestonTJDaltonHJNicolKKFerralBRMillerJCHayesDJr.Plasma exchange on venovenous extracorporeal membrane oxygenation with bivalirudin anticoagulation. World J Pediatr Congenit Heart Surg2015; 6: 119–122.
47.
ObengEAHarneyKMMonizTArnoldANeufeldEJTrenorCCIII. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk and application of the 4Ts scoring system. J Pediatr2015; 166: 144–150.
48.
LubenowNGreinacherA. Drugs for the prevention and treatment of thrombosis in patients with heparin induced thrombocytopenia. Am J Cardiovasc Drugs2001; 1: 429–443.
49.
ArepallyGMOrtelTL. Heparin-induced thrombocytopenia. N Engl J Med2006; 355: 809–817.
PadmanabhanAJonesCGPechauerSMet al. Intravenous immunoglobulin for treatment of severe refractory heparin-induced thrombocytopenia. Chest2017; 152: 478–485.
52.
WelsbyIJUmJMilanoCAOrtelTLArepallyG. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg2010; 110: 30–35.
53.
MulderMMGFawzyILancéMD. ECMO and anticoagulation: a comprehensive review. Neth J Crit Care2018; 26: 6–13
54.
YoungG. Anticoagulants in children and adolescents. Hematology Am Soc Hematol Educ Program2015; 2015: 111–116.
55.
ChanVMonaglePMassicottePChanA. Novel pediatric anticoagulants: a review of the current literature. Blood Coagul Fibrinolysis2010; 21: 144–151.
56.
YoungGBoshkovLKSullivanJEet al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer2011; 56: 1103–1109.
57.
KawadaTKitagawaHHosonMOkadaYShiomuraJ. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am2000; 14: 445–457.
58.
PhillipsMRKhouryALAshtonRFCairnsBACharlesAG. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care2014; 42: 97–98.
SellengKWarkentinTEGreinacherA. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med2007; 35: 1165–1176.
61.
GatesRYostPParkerB. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs2010; 34: 667–669.
62.
CasserlyIPKereiakesDJGrayWAet al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res2004; 113: 115–121.
63.
JabrKJohnsonJHMcDonaldMHet al. Plasma-modified ACT can be used to monitor bivalirudin (angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol2004; 36: 174–177.
64.
RanucciMBallottaAKandilHet al. Bivalirudin-based vs. conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care2011; 15: R275.
65.
von VajnaEAlamRSoTY. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol Ther2016; 5: 19–41.
66.
WillmannSBeckerCBurghausRet al. Development of a pediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet2014; 53: 89–102.
67.
YoungGKubitzaDChanAet al. Development of a rivaroxaban dosing regimen for treatment of VTE in children aged 12 to 18 years. J Throm Haemost2015; 13(Suppl 2): 37.
68.
BayerAG. Rivaroxaban pharmacokinetics/pharmacodynamics (PK/PD) study in pediatric subjects. Bethesda, MD: National Library of Medicine (US). 2000. NLM Identifier: NCT01145859. https://clinicaltrials.gov/ct2/show/NCT01145859 [accessed 21.04.17].
69.
von VajnaEAlamRSoTY. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol Ther2016; 5: 19–41.
70.
SquibbBristol-Myers. Multiple-dose study apixaban in pediatric subjects with an indwelling central venous catheter. Bethesda, MD: National Library of Medicine (US). 2000. NLM identifier: NCT01195727. https://clinicaltrials.gov/ct2/show/NCT01195727 [accessed 21.04.17].
71.
SanykoDaiichi. A Phase 1, open-label, single-dose, non-randomized study to evaluate pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients. Bethesda, MD: National Library of Medicine (US). 2000. NLM identifier: NCT02303431. https://clinicaltrials.gov/ct2/show/NCT02303431 [accessed 21.04.17].
